In the wake of terrorist attacks, funding is increasing for life science companies engaged in virtually any area of biosecurity. Organizations that produce vaccines and antibiotics, as well as those developing therapeutics, detection systems, and diagnostics, are receiving much-needed attention from government and private sectors.